Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

Fig. 3

ERα positive patients with high progranulin and sortilin co-expression have worse breast cancer-specific survival. a-c Kaplan-Meier curves illustrating breast cancer-specific survival in all ERα positive patients. a BCSS in the double high group (high progranulin, high sortilin expression) against all other combinations (mixed group) in the ERα positive population (n=279). b-c Tamoxifen response shown by BCSS in all ERα positive patients stratified by b double high group (n=55) or c mixed progranulin/sortilin expression (n=224). The statistical differences between the curves, as well as HR and 95% CI were estimated by the log-rank test. BCSS: breast cancer-specific survival, HR: hazard ratio, CI: confidence interval, PGRN: progranulin, SORT: sortilin

Back to article page
\